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Connected Health: An Open Innovation Perspective 
Anushree Priyadarshini*a, Maria Quinlana, and Gerardine Doylea 
 
aApplied Research for Connected Health (ARCH) and UCD College of Business, University College Dublin, 
Belfield, Dublin 4, Ireland  
Abstract: The concept of connected health has gained traction in recent years as a new technology enabled and 
networked model of healthcare delivery. It is often used as an umbrella term for eHealth, digital health, health 
informatics, telemedicine, mHealth and involves the establishment and management of a network of stakeholders 
with the aim of improving healthcare quality and outcomes. Yet a lack of open interactions and knowledge 
networks and the missing integration of the larger constituency of interdisciplinary experts are limiting the 
execution of the model and restricting its potential to devise services and interventions around patient’s needs with 
shared health related data. Drawing parallels between the concept of connected health and open innovation, the 
networked innovation model, which involves efficient management of knowledge flows and complex networks for 
successful innovations; in this paper we outline the practice of open innovation in healthcare and suggest 
connecting stakeholders in the healthcare ecosystem in an open innovative format. In doing so we present a 
categorization of firms in the healthcare ecosystem into open innovation profiles for becoming connected and 
propose an open innovative framework for maximizing the potential of the concept of connected health. 
Keywords: Connected health; Open innovation; Healthcare ecosystem; Innovation network 
1. INTRODUCTION 
 The phenomenon of increasingly networked process of 
innovation in which companies profit from external 
knowledge is called ‘open innovation’, a paradigm that 
assumes that organizations can and should combine internal 
ideas, external ideas and paths to market, as they look to 
advance their technologies [1]. Advantages of this strategy 
are that firms can make use of pooled human resources, 
technology and customer information. These can result in 
speeding up the innovation process, spreading the risk of 
innovation failure, reducing the costs of technological 
development or market entry and improving the achievement 
of economies of scale in production. This apparently new 
paradigm, involves efficient management of knowledge 
flows and complex networks for successful innovations [2, 
3]. 
The concept overlaps well with the diverse features of 
‘connected health’. Indeed, the range of complex 
stakeholders, technologies, objectives and disciplines 
involved in connected health tend to exponentially increase 
its heterogeneity and calls for the establishment and 
management of networks, similar to that which is required in 
an open innovation scenario. Pagilari [4] and Dooris [5] 
suggest that the potential of connected health may be 
maximized by the involvement of a wider community of 
disciplinary experts, including managers and accountants, 
social scientists and legal experts. While it can be argued that 
even though not currently strategically rolled out in practice, 
the open innovation approach forms the premise for the 
concept of connected health to fully flourish [6]. Examples 
like GSK and the Hammersmith Hospital’s collaboration for 
a Clinical Imaging Centre; NHS Trusts in Scotland and 
Wyeth Pharmaceuticals’ Experimental Medicine project are 
fast growing [7]. Yet as outlined by Eaton [8] it is 
noteworthy that the lack of open interactions and knowledge 
networks and the missing integration of the larger 
constituency of interdisciplinary experts are increasingly the 
underlining factor for a missing open innovative framework 
in the healthcare system. Similarly, Brodie [6] also suggests 
that the size, level of complexity of the organization, 
difference in attitudes of the partners and lack of any rewards 
limit the collaborative opportunities in the healthcare arena. 
Therefore as an approach for players in the healthcare 
landscape to be connected, in this paper firstly we propose a 
categorization for firms who operate within the healthcare 
ecosystem into open innovation profiles for becoming 
connected. Secondly we propose an open innovative 
framework for the implementation of connected health. 
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2. OPEN INNOVATION IN HEALTHCARE 
 Healthcare research is under increasing pressure to 
innovate in order to counter rising operational costs and 
depleting pipelines [9]. While currently the focus of 
innovation in healthcare is on patient care and disease 
mitigation [10]; demographic changes, advancements in 
medical science, major scarcities of human and financial 
resources and the increasing empowerment of users is fast 
resulting in a paradigm shift towards prevention, 
participation and coaching [11]. This is essentially a move 
from merely looking at healthcare via the biomedical lens of 
diagnosis and treatment, towards a more holistic social 
model of healthcare which incorporates a person’s wider 
social and cultural factors. Boote et al. [12] argue that for the 
advancement of research and development in health care, it 
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is crucial to integrate the users in health and social research. 
Supporting this stance Dahlander and Gann [13] also suggest 
that although traditionally integration of users in health care 
research was marred by significant costs, advancing 
technologies and usage behaviors today suggest that the 
integration of users into innovation activities has become 
quite feasible and cost-effective.   
Open innovation is increasingly touted as the business model 
for growing value and innovation through partnership. The 
concept, in which organizations collaborate on research with 
users and other external partners, is progressively showing 
strong potential to contribute to improvements in the quality 
of healthcare innovation and delivery [7]. While it is gaining 
traction in the form of typologies like clinicians forming a 
network for healthcare innovation (example: The Society of 
Physician Entrepreneurs) and as public health systems 
encouraging digital health companies to engage with them 
(example: eHealth Connect, Ireland), the key application of 
open innovation in healthcare currently has been 
experimental medicine via patients as innovators [14]. In this 
approach, academic researchers, clinicians and industry 
collaborate with patients for developing healthcare 
innovations. Another avenue has been identification and 
collaboration with persons who suffer from a health problem 
and independently develop solutions for it [14]. For instance, 
in 2004 a British process engineer, Tal Golesworthy, 
diagnosed with Marfan syndrome, designed his own heart 
textile implant when he realized it was better than an aortic 
valve replacement. His ‘lay’ solution has been implanted in 
23 other people since then [15]. Another example is that a 
mother of a young woman with vaginal adenocarcinoma who 
explored and suggested that the cause of the disease might 
have been diethylstilboestrol; the mother of another patient 
was the first to hypothesize that a low maternal serum 
(alpha) fetoprotein concentration might be a marker for 
trisomy [16]. These examples reinforce the significance of 
integrating users in health care research.  
Thus far, integrating the users/care givers in healthcare 
research has largely been limited to the incorporation of 
patients in the reviewing and testing stage of the research 
and development process [12]. However, there is an 
increasing need to move beyond blockbuster drugs and to 
renew the focus on medicines and diagnostics so that smaller 
groups of patients with specific unmet needs can be targeted. 
Merging technology with biology is required so that the 
collection, analysis and sharing of data can result in 
developing clinical insight relating to patient care and 
response to treatments. Having a range of funding sources, 
including from research councils to commercial entities is 
needed and patients must be empowered so that they strive 
for greater participation in decisions relating to the choice of 
their treatment and care. Therefore, further to the just user 
collaboration, a more integrated approach in the healthcare 
sector is called for, a connected health approach, that aligns 
healthcare providers with industry, with caregivers, patients 
and payers to integrate multiple healthcare solutions [7]. 
Given the current technological developments, especially the 
convenience of interactive web-based technologies that 
enable active participation of a wider group of stakeholders, 
this can be achieved by a culture change in healthcare and 
close collaboration between healthcare, industry and 
regulatory stakeholders in an open innovative model [17]. 
3. OPEN INNOVATION PROFILES FOR 
CONNECTED HEALTH 
 To connect stakeholders in the healthcare ecosystem for an 
open innovative format, it is essential to first categories 
companies based on their business needs and the different 
innovation strategies [18]. The classification can assist 
mapping firms based on their business efficiencies and value 
so that it can be identified to whom firms must open, within 
and across categories for successful connections.  
To adapt to the unprecedented change in the healthcare 
industry, firms are adopting different innovation strategies to 
offer healthcare solutions [19], and based on these the 
companies can be categorized as follows: 
Products based: firms that develop product or services and 
progress along the drug development process. These firms 
generate value by either licensing their products to 
pharmaceutical companies or by commercializing them. 
Platforms based: firms that are engaged in improving 
processes and developing new capabilities, internally or 
through collaborations. 
Technology based: firms that develop new technologies for 
all aspects of healthcare. 
Hybrid: firms that are engaged in innovating revenue 
generation, moving from sales of drugs, diagnostics or 
devices. These focus on combining technology and platforms 
with services and the creation of products. 
Growing complexities, advanced technologies and easy access 
to highly qualified experts that are outside the confines of the 
companies, alongside with mounting pressure on time and cost 
is rapidly advancing the development of open innovation in 
the healthcare industry. For example, pioneering the concept, 
Eli Lilly as early as in 2002, established networks of the global 
pharmaceutical companies [20], namely the Fully Integrated 
Pharma Network, the Phenotypic Drug Discovery Initiative, 
the Target Drug Discovery Initiative and Chorus for 
collaborative research [21]. In 2007, GlaxoSmithKline (GSK) 
launched its Centre for Excellence for External Drug 
Discovery, for complete focus on drug discovery alliances 
with external partners [22]. Similarly reducing its R&D budget 
Pfizer in 2010, established Centers for Therapeutic Innovation, 
with an aim to develop global partnerships between Pfizer and 
academic medical centers [23]. While elements of a more 
open business model for pharmaceutical R&D are increasingly 
becoming evident [24], the approach has not been adopted to 
harness open interactions beyond R&D projects where 
healthcare companies are accessing external knowledge either 
to manage limited development times and costs, or for getting 
external information and know-how that companies do not 
have. Open innovative interactions amongst all players in the 
healthcare ecosystem and development of knowledge 
networks based upon profiling of firms as outlined above can 
result in the integration of the larger constituency of 
interdisciplinary experts and can be the underlining factor in 
implementing connected health with an open approach. 
4. OPEN INNOVATION FRAMEWORK FOR 
CONNECTED HEALTH 
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While drawing open innovation profiles for firms in the 
healthcare sector forms the starting point of an open 
approach to connected health, connecting these firms with 
other stakeholders in the ecosystem calls for an 
understanding of the requirements of the concept to build 
solutions.  In this vein it can be envisaged that the demand 
side of developing connected health solutions on the ground 
involves several factors. These include creating a patient’s 
health record; building a lifelong health history for a patient 
from information held in multiple, diverse systems; joining 
the different systems on different platforms; interconnecting 
diverse systems so that they can interoperate; developing 
communication between remote systems and achieving 
performance and scalability [25]. Thus working from the 
requirements towards solutions, taking into consideration the 
current as well as the required perspectives of the 
stakeholders, an open connected health model that involves 
engaging with different parties, is suggested (Fig. 1). 
 
Fig. 1. An open interactive connected health model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The framework outlines that for the healthcare system to be 
integrated and interactive at multiple levels and for open 
interactive connected health to become a reality, continuous 
interoperable health data must flow between patients and 
their care providers bi-directionally in real time. This can be 
achieved by creating an access portal that acquires and 
integrates the data in collaboration with the different players 
in the ecosystem. The key elements required here include 
ensuring access, collection and sharing of information across 
parties; for pharmaceutical firms to work in collaboration 
with patients, care providers and amongst themselves to 
create platforms to achieve digitalization and connectedness 
of the health system. Patients need to become more involved 
in order to better track and manage their health by using 
tools that are outside of traditional medical settings, 
leveraging the formal healthcare system information to 
advance their engagement with their circle of care; and 
services between care providers (hospitals, clinics and third 
parties such as home-care providers and informal care 
providers) to be coordinated through connectivity, allowing 
for seamless collaboration.  
Implementation of this open collaborative approach in 
healthcare, like in other industries requires focusing on the 
operational and ownership complexities [24]. These call for 
firstly exploring the existing openness amongst the different 
players in the ecosystem as against the connected 
framework.  This is to be followed by conducting a gap 
analysis and then designing the execution plan which could 
take different routes. For example routes like strategically 
driven, top-down centralized approach common in fast 
moving consumer goods (FMCG) organizations where the 
market is demanding with high competition and achieving 
revolutionary innovations is difficult [26]; or strategically 
driven, distributed approach as is followed by energy 
companies that in small groups make contacts with potential 
partners for collaboration [27]. Other routes could be bottom 
up evolutionary approaches, either centralized or distributed, 
that are driven by environmental conditions like market 
forces as in the case of the telecommunications industry [28].  
Similarly managing the ownership complexities of 
implementing an open collaborative approach in healthcare 
requires exploring the influence of the network participants 
on getting connected and their flexibility around the outcome 
of participation. Attitudes may vary amongst partners about 
intellectual property (IP) rights [6]. Also misconceptions that 
open innovation underrates and weakens IP protection may 
limit the collaborative approach. Based on the scenario of 
these complexities, agendas and directions can be designed. 
Like defining at the onset of the collaboration the ownership 
and legal rights if an IP is jointly created.  How value will be 
derived by using IP for increasing returns and if goals and 
milestones of the collaboration are not met, identifying what 
would be the potential exit strategies [29].   
5. LIMITATIONS AND RECOMMENDATIONS  
Apart from operational and ownership complexities, 
limitations to achieving a fully connected health care system 
include need for changing workflows and processes. As 
these tend to be engrained in organizational working, 
adopting an open connected health model that involves 
aligning with other organization’s cultures and strategies can 
be quite a limiting factor [29]. The sheer size and complexity 
of certain partners including their bureaucratic imperatives 
may also limit collaborative opportunity [6].While personal 
career priorities and cultural resistance from the healthcare 
professionals may inhibit them from embracing the 
approach. Concerns around lack of evidence on the cost 
effectiveness of the model, lack of a legal and regulatory 
framework, inequality in access to technology to patients and 
care givers and need for common interoperability standards 
may be other factors that are obstacles in the achievement of 
a fully connected health care system [30].  
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Overcoming these limitations for improving networking and 
collaboration, it is critical to first identify outputs that are 
mutually beneficial to all parties. Ensuring trust and 
willingness to share expertise, data, rewards as well as risks 
can add to the relationship and what could be achieved 
through the collaboration [6]. Additionally, an open 
collaborative approach in healthcare requires developing 
clear structures for data protection; security and privacy 
arrangements in place for sharing data from healthcare apps 
with electronic health records. Patients’ involvement can be 
elicited by giving them control of their data with 
mechanisms in place to allow them to see who is using their 
data and for what purposes. Similarly co-designing of 
solutions with healthcare professionals, patients and care 
givers can be harnessed by gathering evidences on the 
economic benefit of their involvement [30]. State can 
support crowd sourcing and crowd funding initiatives and 
can address regulatory challenges by developing incentives 
like open innovation credits, common IP frameworks and 
public private partnerships that can facilitate the 
development of an open collaborative healthcare ecosystem 
[31].      
An open model for practicing connected health is not just 
about collaboration amongst multiple stakeholders across 
disciplines and across levels but also about associations 
beyond regions and nations [32]. It therefore requires 
developing an open culture in organizations where working 
with different players in the ecosystem is accepted and 
endorsed. Procedures like cross functional networks beyond 
borders are followed and skillsets are advanced for open 
collaborative working [33]. By developing global policies 
and creating open innovation-friendly markets and 
regulatory conditions for cross border health services, the 
concept may well be developed as a new open, inclusive, 
multi-stakeholder, user-centric approach that can address the 
contextual challenges of connected health services.        
CONCLUSION 
 There is a need for the healthcare system to adapt to more 
effective ways of developing networks and collaboration that 
span beyond just R&D projects [11]. Open innovation, as 
discussed above is a concept of vital interest in such a scenario. 
It holds important synergies with the connected health approach 
and thus can significantly impact the adoption of the approach 
for sustainable networks and advanced outcomes in the 
healthcare arena. This paper attempts to add to the process of 
better understanding how an open interactive approach can 
maximize the potential of the concept of connected health. We 
categories healthcare firms into open innovation profiles, outline 
examples of open innovation approaches adopted by 
pharmaceutical firms, and propose an open innovation 
framework for connected health. Undoubtedly, connected health 
is a complex concept owing to its heterogeneity and more and 
more future research needs to focus on exploring how the vital 
concept can be integrated in the healthcare system to improve 
and advance outcomes. 
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